APPLIED THERAPEUTICS INC (APLT)

Company Profile

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. The company is headquartered in New York City, New York and currently employs 26 full-time employees. The company went IPO on 2019-05-09. The company is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The firm is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. The company has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

Company Info

APPLIED THERAPEUTICS INC

545 Fifth Avenue, Suite 1400

New York City NEW YORK 10017

P: 12122209226

CEO: Shoshana Shendelman

Employees: 26

Website: https://www.appliedtherapeutics.com/